Abstract:Aim: The current research aims to establish a stability-indicating analytical method (SIAM) for the quantification of evodiamine (EVO), characterization of its degradation impurity, and establishment of possible degradation pathways. Background: None of the degradation impurities of EVO is known and the mechanism of their formation has not been reported in any literature to date. Moreover, a SIAM for EVO is not available in any public domain. Objective: The objective of this study is to characterize the degradation impurity of EVO by LC-MS/MS, proposing its molecular structure, identifying possible degradation pathways of generation of its impurity, and establishing a SIAM. Method: To assist future product development, a degradation study of EVO was performed and an RP-HPLC-based SIAM was developed. The major degradation product was characterized by LC-Q-TOF-MS/MS. In addition, in silico toxicity prediction was performed using the ProTox-ІI toxicity predictor. Result: The method was found to be linear, accurate, precise, and robust over the range of 12.5 to 100 μg /mL of EVO. The method met all the acceptance criteria as specified in the ICH guideline. Only one degradation product (9% of the drug area) of EVO was generated in acidic hydrolytic conditions. The degradation product was found to be potentially inactive for hepatotoxicity and immunotoxicity, with a confidence score of more than 0.7 (70%). Moreover, the confidence score for carcinogenicity, mutagenicity, and cytotoxicity was less than 0.7, indicating it was moderately inactive for these toxicities. Conclusion: The molecule was found to be stable in the majority of the tested stress conditions. However, the degradation product generated in acidic hydrolytic stress was characterized using LC-Q-TOF-MS/MS, which was unknown to date. The novelty of this research can be justified by the unavailability of any SIAM of EVO and the absence of any report on its susceptibility to degradation in the presence of different potential stressors. Moreover, the potential toxicity of the molecule and its impurity was not known previously. The reported degradation impurity may be useful to set the quality control acceptance criteria for EVO. Additionally, pharmaceutical industries and research laboratories may use the developed method for the analysis of quality control and stability samples of EVO.

Study in the synthesis and crystal structure of the potentially genotoxic impurity E of Avanafil

Synthesis and mutagenic risk of avanafil's potential genotoxic impurities

Identification, synthesis and characterization of avanafil process impurities and determination by UPLC

Exploring the Structural Landscape for a Thrombopoietin Receptor Agonist Avatrombopag Maleate: an Innovative Trihydrate Forms with Improved Solubility Found

Convenient Synthesis and Characterization of Novel 4-[2-ethoxy-5-(4-methyl-1-piperazinesulphonyl)benzamido]-3-isobutyl-1-methyl-1h-pyrazole-5-carboxamide: Key Precursor for Isobutyl Sildenafil

Analysis of the Genotoxic Impurity S-(+)-Epichlorohydrin Contained in (S)-Oxiracetam Using Gas Chromatography

A Drug–Excipient Interaction Impurity of Bromhexine Hydrochloride Injection: Structure and Formation Mechanism Elucidation

Synthesis, structural characterization, physicochemical properties and transformations of dehydroevodiamine and its hydrochloride salts

Identification and quantitative analysis of genotoxic impurities in rifampicin: Development and validation of a targeted LC-MS/MS method for 1-amino-4-methylpiperazine

Development of Validated and Stability-Indicating LC-DAD and LC-MS/MS Methods for Determination of Avanafil in Pharmaceutical Preparations and Identification of a Novel Degradation Product by LCMS-IT-TOF

Isolation, structural characterization and quality control strategy of an unknown process-related impurity in sugammadex sodium

Synthesis, crystal structure, DFT, vibrational properties, Hirshfeld surface and antitumor activity studies of a new compound 2-(2-chloro-6-(m-tolyl)imidazo[1,2-a]pyridin-3-yl)-N,N-diethylacetamide

An innovative impurity profiling of esmolol hydrochloride injection using UPLC-MS based multiple mass defect filter, chemometrics and in-silico toxicity prediction

Validated Stability Indicating HPTLC and UV-Spectrophotometric Techniques for the Determination of Avanafil

LC/Q‐TOF‐MS‐based structural characterization of enasidenib degradation products and establishment of a stability‐indicating assay method: Insights into chemical stability

Structural analysis of anti-retroviral drug raltegravir and its potential impurity C: investigation of solubility and stability

Improved Synthetic Methodology, Substrate Scope and X‐ray Crystal Structure for N, N'‐disubstituted Guanidines

Identification, Synthesis, and Characterization of Potential Dichloro Impurity: N,N-Dimethyl-3-Phenyl-2, 3-Dichloropropylamine in the Synthesis of Atomoxetine

Stability Indicating Analytical method, Characterization of Degradation Impurity by UPLC-Q-TOF-MS/MS, and Establishment of Degradation Mechanism of Evodiamine

Methyl Scanning Approach for Enhancing the Biological Activity of the Linear Peptidic Natural Product, Efrapeptin C

Identification, trace level quantification, and in silico assessment of potential genotoxic impurity in Famotidine